



00270

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	10/074,768
Filing Date	02/12/2002
First Named Inventor	Puwen Zhang et al
Group Art Unit	1624
Examiner Name	T. Truong
Attorney Docket Number	AHPWA6BUSA

Total Number of Pages in This Submission 24

ENCLOSURES (check all that apply)

- ☐ Fee Transmittal Form
 - ☐ Fee Attached
- ☐ Amendment / Reply
 - ☐ After Final
 - ☐ Affidavits/declaration(s)
- ☐ Extension of Time Request
- ☐ Express Abandonment Request
- ☒ Information Disclosure Statement
- ☐ Certified Copy of Priority Document(s)
- ☐ Response to Missing Parts/Incomplete Application
 - ☐ Response to Missing Parts under 37 CFR 1.52 or 1.53

- ☐ Assignment Papers (for an Application)
- ☐ Drawing(s)
- ☐ Licensing-related Papers
- ☐ Petition
- ☐ Petition to Convert to a Provisional Application
- ☐ Power of Attorney, Revocation Change of Correspondence Address
- ☐ Terminal Disclaimer
- ☐ Request for Refund
- ☐ CD, Number of CD(s) _____

- ☐ After Allowance Communication to Group
- ☐ Appeal Communication to Board of Appeals and Interferences
- ☐ Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
- ☐ Proprietary Information
- ☐ Status Letter
- ☒ Other Enclosure(s) (please identify below):

Copies of (29) documents are attached hereto

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm
or
Individual nameCathy A. Kodroff, Esquire
Howson and Howson

Signature

Date

4-17-2002

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date:

Typed or printed name

Signature

Date

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

3
5/22/02
92



00270

PATENT TRADEMARK OFFICE

AHPWA6BUSA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of

Puwen Zhang et al

Appln. No. 10/074,768 ✓

Filed: February 12, 2002 ✓

For: BENZIMIDAZOLONES AND
ANALOGUES ✓

) Group Art Unit: 1624

)

) Examiner: T. Truong

)

)

)

)

)

) FILED BY HAND-DELIVERY

) April 17, 2002

RECEIVED
APR 17 2002
PTO

Assistant Commissioner for Patents
Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants submit to the Examiner the attached Form PTO/SB/08A/B document listing and this paper pursuant to 37 CFR §1.56 and § 1.97-1.98. Form PTOSB/08A/B and this paper identify documents previously cited in the parent application, U.S. Patent Application No. 09/552,546, filed April 19, 2000, currently pending.

According to 37 CFR § 1.98(d), Applicants have not enclosed copies of any U.S. patents, publications or other documents listed herein, which listed items were previously cited by or submitted to the United States Patent and Trademark Office in parent U. S. Patent Application No. 09/552,546, filed April 19, 2000, (pending). The parent patent application is relied upon herein for an earlier priority date under 35 USC § 120.

This Information Disclosure Statement is submitted within three months of the filing date of this application, and prior to receipt of an Office Action on the merits. Therefore, no fees are believed due. However, the Director of the U. S. Patent and Trademark Office is hereby authorized to charge any deficiency in any fees due with the filing of this paper or credit any overpayment in any fees paid on the filing, or during prosecution of this application to Deposit Account No. 08-3040.

Listed below are co-pending U.S. Patent applications and patents which were filed on the same date as parent U. S. Patent Application No. 09/552,546. These applications and the present application are commonly owned.

- (1) U.S. Patent Application No. 09/552,633, filed April 19, 2000
U.S. Patent Application No. 09/948,309, filed September 6, 2001
- (2) U.S. Patent Application No. 09/552,632, filed April 19, 2000
U.S. Patent Application No. 10/014,173, filed December 11, 2001
- (3) U.S. Patent Application No. 09/552,352, filed April 19, 2000
- (4) U.S. Patent No. 6,355,648, issued March 12, 2002
U.S. Patent Application No. 10/022,467, filed October 30, 2001
U.S. Patent Application No. , filed April 5, 2002
- (5) U.S. Patent Application No. 09/552,354, filed April 19, 2000
- (6) U.S. Patent No. 6,339,098, issued January 15, 2002
- (7) U.S. Patent No. 6,306,851, issued October 23, 2001
U.S. Patent Application No. 09/906,875, filed July 17, 2001
- (8) U.S. Patent No. 6,369,056, issued April 9, 2002
U.S. Patent Application No. 10/050,287, filed January 16, 2002
- (9) U.S. Patent No. 6,358,948, issued March 19, 2002
U.S. Patent Application No. 10/023,063, filed December 17, 2001
- (10) U.S. Patent Application No. 09/552,544, filed April 19, 2000
U.S. Patent Application No. 10/043,513, filed January 9, 2002

- (11) U.S. Patent Application No. 09/552,357, filed April 19, 2000
- (12) U.S. Patent Application No. 09/552,037, filed April 19, 2000
- (13) U.S. Patent Application No. 09/552,350, filed April 19, 2000
- (14) U.S. Patent No. 6,329,416, issued December 11, 2001
U.S. Patent Application No. 09/977,790, filed October 15, 2001
- (15) U.S. Patent Application No. 09/552,355, filed April 19, 2000
U.S. Patent Application No. 10/091,222, filed March 1, 2002
- (16) U.S. Patent Application No. 09/552,545, filed April 19, 2000
- (17) U.S. Patent Application No. 09/552,358, filed April 19, 2000
- (18) U.S. Patent No. 6,319,912, issued November 20, 2001
- (19) U.S. Patent No. 6,358,947, issued March 19, 2002

English translations of documents (AN) and (BM) were not available. However, document (AI), U.S. Patent No. 5,414,088, issued May 9, 1995, corresponds to document (AN), International Patent Application No. WO91/04974, published April 18, 1991. Similarly, document (AF), U.S. Patent No. 4,831,027, issued May 16, 1989, corresponds to document (BM), German Patent No. 3,633,861, issued April 7, 1988. Further, document (AAU), is the corresponding Chemical Abstracts entry to document (AF). Brief remarks on these documents follow.

Document (AN) describes the preparation of bicyclobenzimidazoles and their use to inhibit erythrocyte and thrombocyte aggregation. Thus, these compounds are used to treat conditions such as arterial occlusive or ischaemic conditions, venous insufficiency or diabetes mellitus.

Document (BM) describes the preparation of imidazobenzoxazinones, and pharmaceutical compositions containing them. These compounds are used in the treatment of cardiovascular effects, particularly cardiotonic activity and antithrombotic activity, with little effect on blood pressure.

English translations of documents (BL), (BN), and (BP) were not available. Abstracts of these documents were provided as documents (BBU), (BBV), and (BBW) respectively. Brief remarks on these documents follow.

Document (BL) describes the preparation and use of imidazopyridine derivatives as platelet agglutination inhibitors, anti-allergic, anti-inflammatory sedative, cardiac and cardiovascular vasodilators.

Document (BN) describes the preparation of pharmaceutical compositions of novel derivatives of benzimidazoles and azabenzimidazoles, which have cardiotonic, vasodilating, anti-hypertensive, anti-aggregation, and anti-ulcer activity. These compositions are useful as cardiotonics, vasodilators, anti-hypertensives, and anti-platelet aggregations agents. Further, these compounds have anti-ulcer activity and can be used in the treatment of gastroduodenal ulcers.

Document (BP) describes the preparation, manufacture, and use of heterocyclic, substituted azoles and azines as herbicides. Particular attention is drawn to their use for selective control of mono- and dicotyledonous weeds and are better tolerated than known compounds of similar structure.

English translations of documents (AM), (AAO) and (AAP) were not available. However, English translations of the abstracts were provided on the front page of the document. Brief remarks on these documents follow.

Document (AM) describes the preparation and use of new bicycloimidazoles. The compounds of the invention are particularly directed toward the use in drugs to prevent clumping of both erythrocytes and thrombocytes.

Document (AAO) describes the combination of one compound having progesterone-antagonistic properties with one compound having anti-oestrogen properties. Each compound is used in a dose that would not inhibit ovulation by itself, but is effective when combined. The medicaments are discussed as being useful in female contraception.

Document (AAP) describes the preparation and use of heterocyclically-substituted 1-indole carboxamides, their pharmaceutically acceptable salts, and use as cyclo-oxygenase-2 inhibitors.

Documents (AAJ) and (AAK) were cited in an Office Action issued in the priority application before its conversion to a provisional application.

English translations of documents (CQ) and (CCL) were provided in the parent application. Additionally, English abstracts of these documents were obtained and provided as documents (BBZ) and (CR), respectively. Brief remarks on these document follow.

Document (CQ) relates to female fertility control comprising intermittent administration of competitive progesterone antagonist together with daily of continuous administration of gestagen. The gestagen may be levonorgestrel, gestodene, desogestrel or cyproterone acetate and the antagonist may be mifepristone or onapriston.

Document (CCL) relates to a contraceptive pack comprising a combination of individual dosage units of competitive progesterone antagonist in an amount which does not inhibit ovulation or promote abortion and individual dosage units of a gestagen for sequential oral administration. Administration can be oral, topical or local.

English translations of documents (BBN) and (CV) were not available. However, English abstracts of these documents were provided on the front cover of the document. Brief remarks on these documents follow.

Document (BBN) describes the use of at least one compound with progesterone antagonistic action and at least one compound with anti-estrogen action, together with partial agonistic action, for drugs useful in hormone replacement therapy.

Document (CV) describes the preparation of 6-aryl- and 6-heteroaryl-2-ethylbenzothiazoles. The electrophilic character of the 2-ethyl-6-benzothiazolyl intermediate radicals is also discussed. A number of the 6-aryl and 6-heteroaryl-2-ethylbenzothiazoles were subsequently utilized to prepare corresponding quaternary salts and spiropyrans.

An English translation of document (BBQ) was not available. However, document (BG), U. S. Patent No. 6,077,840, issued June 20, 2000, corresponds to document (BBQ) and is a parallel document to document (CCP), European Patent No. 947,507. Brief remarks on this document follow.

Document (BBQ) describes a progesterone receptor binding inhibitor which is a tetrahydrobenzindolone derivative of the formula provided. The compound is described as useful as a carcinostatic agent.

Document (BBX) is the full document corresponding to document (AU).

Item (CCY) is a divisional of item (BBA). Because these documents have identical specifications, only a copy of the pending claims is provided for Item (CCY).

Item (CCZ) is a divisional of item (BH). Because these documents have identical specifications, only a copy of the pending claims is provided for Item (CCZ).

Item (DR) is a divisional of item (CW). Because these documents have identical specifications, only a copy of the pending claims is provided for Item (DR).

Item (DS) is a divisional of item (CX). Because these documents have identical specifications, only a copy of the pending claims is provided for Item (DS).

Item (DT) is a divisional of item (BBB). Because these documents have identical specifications, only a copy of the pending claims is provided for Item (DT).

Item (DU) is a divisional of item (BBD). Because these documents have identical specifications, only a copy of the pending claims is provided for Item (DU).

Item (DV) is a divisional of item (CCR). Because these documents have identical specifications, only a copy of the pending claims is provided for Item (DV).

Item (DW) is a divisional of item (BI). Because these documents have identical specifications, only a copy of the pending claims is provided for Item (DW).

Item (DX) is a divisional of item (CCV). Because these documents have identical specifications, only a copy of the pending claims is provided for Item (DX).


Item (DY) is a continuation of item (CCY). Because these documents have identical specifications, only a copy of the pending claims is provided for Item (DY).

The Examiner is respectfully requested to consider the documents identified in this paper and in the attached Form PTO/SB/08A/B during the course of the examination of this application.

Respectfully submitted,

HOWSON AND HOWSON
Attorneys for the Applicants

By

 ✓
Cathy A. Kodroff
Registration No. 33,980
Spring House Corporate Center
Box 457
Spring House, PA 19477
Telephone: (215) 540-9210
Telefacsimile: (215) 540-5818

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/074,768
				Filing Date	February 12, 2002
				First Named Inventor	Puwen Zhang et al
				Group Art Unit	1624
				Examiner Name	T. Truong
Sheet	1	of	16	Attorney Docket Number	AHPWA6BUSA

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	AA	3,635,964	B1	J. Skorcz	01/18/1972	
	AB	3,917,592	B1	J. Kobzina	11/04/1975	
	AC	4,440,785	B1	D. Walsh	04/03/1984	
	AD	4,666,913	B1	D. Kuhla	05/19/1987	
	AE	4,670,566	B1	D. Walsh	06/02/1987	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	AL	WO	WO86/03749	A1	D. Kuhla	07/03/1986		
	AM	WO	WO91/06545	A1	W. von der Saal	05/16/1991		
	AN	WO	WO91/04974	A1	W. von der Saal	04/18/1991		
	AO	WO	WO93/12085	A1	B. Boar	06/24/1993		
	AP	WO	WO94/14434	A1	J. Elliott	07/07/1994		
	AQ	WO	WO95/20389	A1	S. Young	08/03/1995		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Substitute for Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/074,768
				Filing Date	February 12, 2002
				First Named Inventor	Puwen Zhang et al
				Group Art Unit	1624
				Examiner Name	T. Truong
Sheet	2	of	16	Attorney Docket Number	AHPWA6BUSA

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	AF	4,831,027	B1	B. Narr	05/16/1989	
	AG	4,853,473	B1	R. Fischer	08/01/1989	
	AH	5,171,851	B1	M. Kim	12/15/1992	
	AI	5,414,088	B1	W. von der Saal	05/09/1995	
	AJ	5,453,516	B1	R. Fischer	09/26/1995	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	AAL	WO	WO95/20972	A1	G. Hodgen	08/10/1995		
	AAM	WO	WO95/33746	A1	B. Kamireddy	12/14/1995		
	AAN	WO	WO96/19458	A1	T. Jones	06/27/1996		
	AAO	WO	WO96/19997	A1	K. Chwalisz	07/04/1996		
	AAP	WO	WO97/13767	A1	D. Binder	04/17/1997		
	AAQ	WO	WO98/14436	A1	D. Christ	04/09/1998		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Substitute for Form 1449/A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/074,768
				Filing Date	February 12, 2002
				First Named Inventor	Puwen Zhang et al
				Group Art Unit	1624
				Examiner Name	T. Truong
Sheet	3	of	16	Attorney Docket Number	AHPWA6BUSA

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	AK	5,681,817	B1	G. Hodgen	10/28/1997	
	AAA	5,521,166	B1	G. Grubb	05/28/1996	
	AAB	5,688,808	B1	T. Jones	11/18/1997	
	AAC	5,688,810	B1	T. Jones	11/18/1997	
	AAD	5,693,646	B1	T. Jones	12/02/1997	

FOREIGN PATENT DOCUMENTS								
Examiner Initials ²	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	BL	JP	63112584			05/17/1988		
	BM	DE	3,633,861		B. Narr	04/07/1988		
	BN	EP	385,850		N. Bru-Magniez	09/05/1990		
	BO	EP	510,235		M. Kim	10/28/1992		
	BP	EP	311,135		M. Ganzer	04/12/1989		
	BQ	EP	022,317		T. Watanabe	01/14/1981		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/074,768
				Filing Date	February 12, 2002
				First Named Inventor	Puwen Zhang et al
				Group Art Unit	1624
				Examiner Name	T. Truong
Sheet	4	of	16	Attorney Docket Number	AHPWA6BUSA

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	AAE	5,693,647	B1	T. Jones	12/02/1997	
	AAF	5,696,127	B1	T. Jones	12/09/1997	
	AAG	5,696,130	B1	T. Jones	12/09/1997	
	AAH	5,696,133	B1	T. Jones	12/09/1997	
	AAI	5,719,136	B1	K. Chwalisz	02/17/1998	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	BBL	EP	454,330		H. Hara	10/30/1991		
	BBM	WO	WO94/29272	A1	B. Boar	12/22/1994		
	BBN	WO	WO95/11013	A1	K. Chwalisz	04/27/1995		
	BBO	WO	WO96/15794	A1	D. Spicer	05/30/1996		
	BBP	WO	WO97/49407	A1	H. Coelingh Bennink	12/31/1997		
	BBQ	WO	WO98/27059	A1	K. Kurihara	06/25/1998		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/074,768
				Filing Date	February 12, 2002
				First Named Inventor	Puwen Zhang et al
				Group Art Unit	1624
				Examiner Name	T. Truong
Sheet	5	of	16	Attorney Docket Number	AHPWA6BUSA

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	AAJ	5,475,020	B1	J. Johnson	12/12/1995	
	AAK	5,007,952	B1	T. Kume	04/16/1991	
	BA	4,093,730	B1	A. Butti	06/06/1978	
	BB	4,822,794	B1	A. Spada	04/18/1989	
	BC	4,721,721	B1	D. Kuhla	12/26/1988	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	CL	WO	WO98/55116	A1	M. Goulet	12/10/1998		
	CM	WO	WO99/11264	A1	K. Widdowson	03/11/1999		
	CN	EP	208,510		S. Kadin	01/14/1987		
	CO	EP	483,077		F. Fraschini	09/27/1991		
	CP	EP	535,529		T. Takahashi	09/24/1992		
	CQ	DE	4330234		K. Chwalisz	03/09/1995		✓

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/074,768
				Filing Date	February 12, 2002
				First Named Inventor	Puwen Zhang et al
				Group Art Unit	1624
				Examiner Name	T. Truong
Sheet	6	of	16	Attorney Docket Number	AHPWA6BUSA

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	BD	5,733,902	B1	M. Schneider	03/31/1998	
	BE	5,808,139	B1	I. Pathirana	09/15/1998	
	BF	5,874,430	B1	D. Christ	02/23/1999	
	BG	6,077,840	B1	K. Kurihara	06/20/2000	
	BH	6,306,851	B1	A. Santilli	10/23/2001	

FOREIGN PATENT DOCUMENTS								
Examiner Initials ²	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	CCL	DE	4344463		K. Stockemann	06/29/1995		✓
	CCM	WO	WO99/44608	A1	J. Ramachandran	09/10/1999		
	CCN	WO	WO99/15500	A1	S. Davis	04/01/1999		
	CCO	WO	WO99/10325	A1	R. McNutt	03/04/1999		
	CCP	EP	947,507		K. Kurihara	10/06/1999		
	CCQ	EP	978,279		V. Roth	02/09/2000		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/074,768
				Filing Date	February 12, 2002
				First Named Inventor	Puwen Zhang et al
				Group Art Unit	1624
				Examiner Name	T. Truong
Sheet	7	of	16	Attorney Docket Number	AHPWA6BUSA

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	BI	6,329,416	B1	G. Grubb	12/11/2001	
	BJ	6,319,912	B1	G. Grubb	11/20/2001	
	BK	6,339,098	B1	M. Collins	01/15/2002	
	BBA	6,355,648	B1	A. Fensome	03/12/2002	
	BBB	6,358,948	B1	P. Zhang	03/19/2002	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/074,768
				Filing Date	February 12, 2002
				First Named Inventor	Puwen Zhang et al
				Group Art Unit	1624
				Examiner Name	T. Truong
Sheet	8	of	16	Attorney Docket Number	AHPWA6BUSA

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	BBC	6,358,947	B1	L. Zhi	03/19/2002	
	BBD	6,369,056	B1	P. Zhang	04/09/2002	
	BBE	5,767,131	B1	C. Gluchowski	06/16/1998	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)

Substitute for Form 1449/A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/074,768
				Filing Date	February 12, 2002
				First Named Inventor	Puwen Zhang et al
				Group Art Unit	1624
				Examiner Name	T. Truong
Sheet	9	of	16	Attorney Docket Number	AHPWA6BUSA

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS				
Examiners Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	AR	R. EVANS, "The Steroid and Thyroid Hormone Receptor Superfamily", Science, 240:889 (May 13, 1988)		
	AS	A. ULMANN et al, "Clinical Uses of Mifepristone (MFP)", Ann. N.Y. Acad. Sci., 261:248 (June 12, 1995)		
	AT	R. KEKKONEN et al, "Sequential Regimen of the Antiprogestone RU486 and Synthetic Progestin for Contraception", Fertility and Sterility, 60(4):610 (October, 1993)		
	AU	K. HORWITZ et al, "Progestin, Progesterone Receptors, and Breast Cancer", Horm. Cancer, publisher: Birkhaeuser, Boston, Mass., ed. Vedeckis, pp. 283-306 (1996) (abstract only)		
	AV	A. MURPHY et al, "Regression of Uterine Leiomyomata in Response to the Antiprogestone RU486", J. Clin. Endo. Metab., 76(2):513 (February, 1993)		
	AW	L. KETTEL et al, "Endocrine Responses to Long-Term Administration of the Antiprogestone RU486 in Patients with Pelvic Endometriosis", Fertility and Sterility, 56(3):402 (September, 1991)		
	AX	H. MICHNA et al, "Differentiation Therapy with Progesterone Antagonists", Ann. N.Y. Acad. Sci., 761:224 (June, 1995)		
	AY	L. ZHI et al, "5-Aryl-1,2-Dihydrochromeno[3,4-f]quinolines: A Novel Class of Nonsteroidal Human Progesterone Receptor Agonists", J. Med. Chem., 41(3):291 (October 22, 1998)		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/074,768
				Filing Date	February 12, 2002
				First Named Inventor	Puwen Zhang et al
				Group Art Unit	1624
				Examiner Name	T. Truong
Sheet	10	of	16	Attorney Docket Number	AHPWA6BUSA

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS				
Examiners Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	AZ	D. COMBS et al, "Nonsteroidal Progesterone Receptor Ligands. 2. High-Affinity Ligands with Selectivity for Bone Cell Progesterone Receptors", J. Med. Chem., 38:4880 (December 8, 1995)		
	AAR	K. PERLMAN et al, "20-Oxopregnacalciferols: Vitamin D Compounds that Bind the Progesterone Receptor", Tet. Letters, 35(15)2295 (1994)		
	AAS	L. HAMANN et al, "Synthesis and Biological Activity of Novel Nonsteroidal Progesterone Receptor Antagonists", Ann. N.Y. Acad. Sci., 761:383 (June 12, 1995)		
	AAT	R. CHEN et al, "Synthesis and SAR of a Novel Series of Spirobenzothlaepine Derivatives with Antiprogesterin Activity", POI-37, 16 th Int. Cong. Het. Chem., Montana (1997)		
	AAU	B. NARR et al, "Preparation, Testing, and Formulation of Imidazobenzoxazinones as Cardiotonics", Chemical Abstracts, 109:22973 (1988)		
	AAV	R. HARTMANN et al, "Effects of Brofoxine, A New Anxiolytic on Experimentally Induced Conflict in Rats", Proc. West. Pharmacol. Soc., 21:51-55 (1978)		
	AAW	B. SINGH et al, "Novel cAMP PDE III Inhibitor" Imidazo[4,5-b]pyridin-2(3H)-ones and Thiazolo[4,5-b]pyridin-2(3H)-ones and their Analogs", J. Med. Chem., 37:248 (January 21, 1994)		
	AAX	A. ANDREANI et al, "Potential Antitumor Agents XVII (1). Cytotoxic Agents from Indole Derivatives and their Intermediates", Acta. Pharm. Nord., 2(6):407 (1990)		
	AAZ	SAKATA et al, "Silver Halide Photographic Materials Useful for Platemaking", Chemical Abstracts, 123:301431 (1993)		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)

Substitute for Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/074,768
				Filing Date	February 12, 2002
				First Named Inventor	Puwen Zhang et al
				Group Art Unit	1624
				Examiner Name	T. Truong
Sheet	11	of	16	Attorney Docket Number	AHPWA6BUSA

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS				
Examiners Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	AAZ	P. PFLEGEL et al, "Polarografie con 7-Chlor-5-phenyl-2-thioxo-1H-2,3-dihydro-1,3,4-benzotriazepinen", Pharmazie, 37(10):714-717 (1982)		
	BR	E. BARENGOLTS et al, "Progesterone Antagonist RU486 has Bone-Sparing Effects in Ovariectomized Rats", Bone, 17(1):21 (July, 1995)		
	BS	E. GROMACHEVSKAYA et al, "Studies of 4H-3, 1-Benzoxazines", Chem. Heterocycl. Cmpds., 33(10):1209-1214 (1997)		
	BT	D. CHIARINO et al, "2,1-Benzisothiazoline 2,2-Dioxide and Derivatives", J. Heterocycl. Chem., 23(6):1645-1649 (November-December, 1986)		
	BU	A. TURCK et al, "On the Metabolism of 3-Substituted and 3,6-Disubstituted Pyridazines", Tetrahedron, 49(3):599-606 (1993)		
	BV	V. KUMAR et al, "Synthesis of 7-Azaindole and 7-Azaoxindole Derivatives through a Palladium-Catalyzed Cross-Coupling Reaction", J. Org. Chem., 57(25):6995-6998 (1992)		
	BW	P. CANONNE et al, "Spirocyclization of 1-(o-Aminophenyl)cycloalkanols and 1-(2'-Amino-3'-pyridinyl)cycloalkanols", J Heterocyclic Chem., 26:113 (January-February, 1989)		
	BX	M-C. FOREST et al, "A Novel Class of Cardiotonic Agents: Synthesis and Biological Evaluation of 5-Substituted 3,6-Dihydrothiadiazin-2-ones with Cyclic AMP Phosphodiesterase Inhibiting and Myofibrillar Calcium Sensitizing Properties", J. Med. Chem., 35:163-172 (January, 1992)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)

Substitute for Form 1449/APTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/074,768
				Filing Date	February 12, 2002
				First Named Inventor	Puwen Zhang et al
				Group Art Unit	1624
				Examiner Name	T. Truong
Sheet	12	of	16	Attorney Docket Number	AHPWA6BUSA

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS				
Examiners Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	BY	D. COMBS et al, "Heteroatom Analogues of Bemoradan: Chemistry and Cardiotonic Activity of 1,4-Benzothiazinylpyridazinones", J. Med. Chem., 35:172-176 (January, 1992)		
	BZ	KURIHARI et al., "Synthesis of (±)-PF1092A, B, and C; New Nonsteroidal Progesterone Receptor Ligands", J. Antibiotics, 50(4):360 (April, 1997)		
	BBR	A. KENDE et al., "Regioselective C-3 Alkylation of Oxindole Dianion", Synth. Commun. 12(1):1 (1982)		
	BBS	T. TUCKER et al., "Synthesis of a Series of 4-(Arylethynyl)-6-Chloro-4-Cyclopropyl-3,4-dihydroquinazolin-2(1H)-ones as Novel Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors", J. Med. Chem., 37:2347-2444 (July 22, 1994)		
	BBT	J. EDWARDS et al., "5-Aryl-1,2-Dihydro-5H-Chromeno[3,4-f]Quinolines as Potent, Orally Active, Nonsteroidal Progesterone Receptor Agonists: The Effect of D-Ring Substituents", J. Med. Chem., 41:303-310 (January 29, 1998)		
	BBU	Derwent WPI abstract, "New Imidazo-Pyridine Derivatives - Useful as Platelet Agglutination Inhibitor, Antiallergic, Antiinflammatory Sedative, Cardiac, and Cardiovascular Vasodilators", JP 63112584		
	BBV	Derwent WPI abstract, N. Brumagniez et al., "Benzimidazole and Azabenzimidazole(s) - Having Cardiotonic, Vasodilating, Anti-Hypertensive, Anti-Aggregation, and Anti-Ulcer Activity", EP 385850		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/074,768
				Filing Date	February 12, 2002
				First Named Inventor	Puwen Zhang et al
				Group Art Unit	1624
				Examiner Name	T. Truong
Sheet	13	of	16	Attorney Docket Number	AHPWA6BUSA

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS				
Examiners Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	BBW	Derwent WPI abstract, F. Arndt et al., "New Heterocycle substituted Benzo-Fused Azine and Azole Derivatives - Useful as Selective Herbicides for Pre or Post-Emergence Application", EP 311135		
	BBX	K. HORWITZ et al., "Progestin, Progesterone Receptors, and Breast Cancer", "Hormones and Cancer", publisher: Birkhaeuser, Boston, Mass., ed. Vedeckis, pg. 283-306 (1996)		
	BBY	V. MAMAEV et al., "Synthesis of 4H-Thieno [3,2-B] Pyrrol-5(6H)-One" Bulletin of the Academy of Sciences on the USSR. Division of Chemical Science, US, Consultants Bureau. New York. Vol. 9, p. 1549-1553, (1966)		
	BBZ	Derwent WPI Abstract, K. CHWALISZ et al. "Female Contraceptive Method Comprises Gestation Treatment with Intermittent Progesterone Antagonist Administration.", DE 4,330,234		
	CR	Derwent WPI Abstract, K. CHWALISZ et al. "Contraceptive Pack for Implantation Inhibition - Contains Competitive Progesterone Antagonist and Gestagen for Sequential Oral Administration.", DE 4,344,463		
	CS	K. KOLASA et al., "Preliminary Pharmacological Studies of the Central Action of Phenyl and Piperidinomethyl Derivatives of 2-Benzoxazolone", Chemical Abstracts, Vol. 99, No. 1, Abst. No.157a (July 4, 1983)		
	CT	N. MEANWELL et al., "Regiospecific Functionalization of 1,3-dihydro-2H-Benzimidazol-2-One and Structurally Related Cyclic Urea Derivatives", J. Organic Chem., 60(6):1565-82 (March 24, 1995)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)

Substitute for Form 1449/A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/074,768
				Filing Date	February 12, 2002
				First Named Inventor	Puwen Zhang et al
				Group Art Unit	1624
				Examiner Name	T. Truong
Sheet	14	of	16	Attorney Docket Number	AHPWA6BUSA

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiners Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CU	B. SINGH et al., "An Efficient and Novel Synthesis of Fused Thiazol-2(3H)-ones" Heterocycles, 36(1):133-134, p. 136, compounds 16a, 18a (January 1993)	
	CV	G. VERNIN et al., "Etude Dans la Serie des Radicaux Heterocycliques. Partie XV. Decomposition aprotique de l' amino-6-ethyl-2-benzothiazole dans des substrats aromatiques et heteroaromatiques: preparation des mesityl-6- et furyl-6-ethyl-2-benzothiazoles, des sels quaternaires et des spiropyranes correspondants", Helvetica Chimica Acta, 62(1/3):21-30 (January 24, 1979)	
	CW	P. ZHANG et al, "Cyclocarbamate Derivatives as Progesterone Receptor Modulators", U. S. Patent Application No. 09/552,633, filed April 19, 2000	
	CX	A. FENSOME et al, "Indoline Derivatives", U. S. Patent Application No. 09/552,632, filed April 19, 2000	
	CY	J. ULLRICH et al, "3,3-Substituted Indoline Derivatives", U. S. Patent Application No. 09/552,352, filed April 19, 2000	
	CZ	P. ZHANG et al, "Cyclothiocarbamate Derivatives as Progesterone Receptor Modulators", U. S. Patent Application No. 09/552,354, filed April 19, 2000	
	CCR	M. COLLINS et al, "Cyanopyrroles", U. S. Patent Application No. 09/552,544, filed April 19, 2000	
	CCS	G. GRUBB et al, "Cyclic Regimens Using Quinazolinone and Benzoxazine Derivatives", U. S. Patent Application No. 09/552,357, filed April 19, 2000	
	CCT	G. GRUBB et al, "Cyclic Regimens Using Cyclic Urea and Cyclic Amide Derivatives", U. S. Patent Application No. 09/552,037, filed April 19, 2000	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/074,768
				Filing Date	February 12, 2002
				First Named Inventor	Puwen Zhang et al
				Group Art Unit	1624
				Examiner Name	T. Truong
Sheet	15	of	16	Attorney Docket Number	AHPWA6BUSA

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiners Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CCU	G. GRUBB et al, "Combination Regimens Using Progesterone Receptor Modulators", U. S. Patent Application No. 09/552,350, filed April 19, 2000	
	CCV	G. GRUBB et al, "Combination Therapies Using Benzimidazolones", U. S. Patent Application No. 09/552,355, filed April 19, 2000	
	CCW	G. GRUBB et al, "Cyclic Regimens Using Cyclocarbamate and Cyclic Amide Derivatives", U. S. Patent Application No. 09/552,545, filed April 19, 2000	
	CCX	G. GRUBB et al, "Cyclic Regimens Utilizing Indoline Derivatives", U. S. Patent Application No. 09/552,358, filed April 19, 2000	
	CCY	A. FENSOME et al, "Thio-Oxindole Derivatives", U. S. Patent Application No. 10/022,467, filed October 30, 2001 (division of (BBA) cited above)	
	CCZ	A. SANTILLI et al, "Cyclocarbamate and Cyclic Amide Derivatives", U. S. Patent Application No. 09/906,875, filed July 17, 2001 (division of (BH) cited above)	
	DR	P. ZHANG et al, "Cyclocarbamate Derivatives as Progesterone Receptor Modulators", U. S. Patent Application No. 09/948,309, filed September 6, 2001 (division of (CW) cited above)	
	DS	A. FENSOME et al, "Indoline Derivatives", U. S. Patent Application No. 10/014,173, filed December 11, 2001 (division of (CX) cited above)	
	DT	P. ZHANG et al, "Quinazolinone and Benzoxazine Derivatives as Progesterone Receptor Modulators", U. S. Patent Application No. 10/023,063, filed December 17, 2001 (division of (BBB) cited above)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/074,768
				Filing Date	February 12, 2002
				First Named Inventor	Puwen Zhang et al
				Group Art Unit	1624
				Examiner Name	T. Truong
Sheet	16	of	16	Attorney Docket Number	AHPWA6BUSA

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiners Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	DU	P. ZHANG et al, "Cyclic Urea and Cyclic Amide Derivatives", U. S. Patent Application No. 10/050,287, filed January 16, 2002 (division of (BBD) cited above)	
	DV	M. COLLINS et al, "Cyanopyrroles", U. S. Patent Application No. 10/043,513, filed January 9, 2002 (division of (CCR) cited above)	
	DW	G. GRUBB et al, "Combination Regimens Using 3,3-Substituted Indoline Derivatives", U. S. Patent Application No. 09/977,790, filed October 15, 2001 (division of (BI) cited above)	
	DX	G. GRUBB et al, "Combination Therapies Using Benzimidazolones", U.S. Patent Application No. 10/091,222, filed March 1, 2002 (division of (CCV) cited above)	
	DY	A. FENSOME et al, "Thio-Oxindole Derivatives", U. S. Patent Application filed April 5, 2002 (continuation of (CCY) cited above)	
	DZ	A. SCHERING et al, "Utilization of Progestins and Competitive Progesterone Antagonists for the Preparation of Medications for Female Fertility Control as Well as Substances Containing a Progestin and a Competitive Progesterone Antagonist", English Translation of German Patent No. DE 4330234, issued March 9, 1995	
	DDR	A. SCHERING et al, "Compound Product for Contraception", English Translation of German Patent No. DE4344463, issued June 29, 1995	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.